

# WEALTH WEEKLY

## Weekly Alerts You Can Use!

### Weekly View: Nifty, Bank Nifty:

Indices	CMP	Support	Resistance	50 DMA	200 DMA	Range	Preferred Trade
NIFTY	24837	24473	25221	25056	24057	24599-25188	Buy only above 25000. Targets at 25401/25670. Stop at 24599
BANK NIFTY	56529	55100	57500	56336	52472	55200-57300	Sell at CMP. Targets at 55100/54501/53899. Stop 57600.

### Medium Term Pick:

Stocks	CMP	Support	Resistance	50 DMA	200 DMA	Bias	Preferred Trade
CIPLA	1532	1289	1702	1492	1491	Positive	Established in 1935, <b>Cipla</b> is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Cipla, with a strong respiratory and generics portfolio is widely acknowledged for its strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments. We remain pretty bullish on the Indian pharma sector amidst a defensive play, especially on large-cap pharma stock like Cipla, citing undervaluation and growth potential. Strong net cash: Net cash position of INR 10,379 Cr; Debt primarily includes lease liabilities and working capital requirements. Major supports are now placed at 1375-1400 zone. The 200 DMA is placed at 1491 levels. The sequence of higher high/low is still intact on all time frames. Now above 1575-mark, momentum buying is quite likely. <b>Simply buy at CMP, and on dips between 1375-1400 zone, targeting 1575/1702 mark and then at 1851 mark. Stop below 1289. Holding Period: 9-12 Months.</b>

#### BUY CIPLA CMP 1532, Targets 1702

CMP	1532
Target Price	1702
52 Week H/L	1702/1310.05
P/E	23.98
EPS (TTM)	63.85
Promoter Holding/DIIs/FIIs	29.19/29.3/25.2
Book Value	396.75
Market Cap (INR)	1,23,674.79 crores

#### Theme:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets.

Cipla, with a strong respiratory and generics portfolio is widely acknowledged for its strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments.

The firm has 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Jun'25), 2nd Largest in the pharma prescription market in South Africa (IQVIA MAT May'25), and 3rd largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT May'25).

We remain pretty bullish on the Indian pharma sector amidst a defensive play, especially on large-cap pharma stock like Cipla, citing undervaluation and growth potential. Buy at CMP and add on dips should be the preferred strategy.

#### Cipla Q1 FY26 Highlights (Consolidated, YoY)

- # Profitability Momentum Continues with Strong EBITDA Margin at 25.6%.
- # Revenue up 3.9% to Rs 6,957 crore versus Rs 6,694 crore.
- # Ebitda up 3.6% to Rs 1,778 crore versus Rs 1,717 crore.
- # Net profit up 10.2% to Rs 1,298 crore versus Rs 1,178 crore.

#### Key Highlights for the quarter:

- # One-India: One India Business delivered a growth of 6% YoY for the quarter, breaching the threshold of INR 3,000 Cr for the first time ever in the opening quarter of any financial year.
- # North America: Delivered quarterly revenue of \$ 226 Mn supported by traction in differentiated assets. Launched Nano Paclitaxel vials (ANDA) and Nilotinib Capsules (NDA).
- # R&D investments: Stood at INR 432 Cr or 6.2% of sales, driven by product filings and development efforts.
- # Strong net cash: Net cash position of INR 10,379 Cr; Debt primarily includes lease liabilities and working capital requirements.

**Technical Outlook:** The stock at the moment is witnessing massive bullish consolidation breakout on the long-term charts and that's on backdrop of one way up move since March 2020 low at Rs 355.

Major supports are now placed at 1375-1400 zone. The 200 DMA is placed at 1491 levels. The sequence of higher high/low is still intact on all time frames. Now above 1575-mark, momentum buying is quite likely.

**Preferred Strategy:** Simply buy at CMP, and on dips between 1375-1400 zone, targeting 1575/1702 mark and then at 1851 mark. Stop below 1289. Holding Period: 9-12 Months.

#### Daily Chart of CIPLA :

